Navigation Links
Quest Diagnostics Completes Acquisition of S.E.D. Medical Laboratories
Date:1/6/2012

MADISON, N.J., Jan. 6, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the successful completion of its previously announced agreement with Lovelace Health System to acquire S.E.D. Medical Laboratories. Under the terms of the transaction, Quest Diagnostics has acquired the assets of S.E.D. Medical Laboratories and will manage in-patient labs for the four Lovelace hospitals, as well as serve Lovelace Health Plan members. Financial terms of the transaction were not disclosed.

Based in Albuquerque, New Mexico, S.E.D. Medical Laboratories is a nationally recognized full-service medical and federally certified drugs-of-abuse testing laboratory with a staff of 450. S.E.D. operates from a modern 50,000 square-foot facility with state-of-the-art equipment and cutting-edge technology. The acquisition includes the transfer of the main offices and lab on Office Boulevard near I-25 and Jefferson, nine Patient Service Centers in Albuquerque and Rio Rancho and six additional locations across New Mexico. 

About Quest Diagnostics
Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at: www.QuestDiagnostics.com.

Contacts:
Kathleen Valentine (Investors): 973-520-2900
Gary Samuels (Media): 973-520-2800

 


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
2. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
3. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
4. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
5. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
6. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
7. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
8. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
11. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the leading ... with Tennessee Counseling Association. This new relationship allows TherapySites to continue ... Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited about ...
(Date:6/27/2016)... ... June 27, 2016 , ... ePAY ... partnership with Connance, a healthcare industry leader providing predictive analytics to optimize ... combine to provide health systems, hospitals and ambulatory surgical centers with dramatic ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):